<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23408" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Immunotherapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Justiz Vaillant</surname>
            <given-names>Angel A.</given-names>
          </name>
          <aff>University of the West Indies</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nessel</surname>
            <given-names>Trevor A.</given-names>
          </name>
          <aff>MSU College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Angel Justiz Vaillant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Trevor Nessel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23408.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Immunotherapy is a pivotal intervention in managing a spectrum of immunological disorders, from immunodeficiencies to malignancies. This&#x000a0;activity&#x000a0;discusses&#x000a0;the diverse modalities of immunotherapy, their mechanisms of action, potential adverse events, and crucial considerations such as dosing and monitoring. Participants will explore the conditions amenable to immunotherapeutic interventions&#x000a0;to better comprehend immunotherapy's role in enhancing the quality of life and longevity of afflicted individuals.&#x000a0;Attendees will gain additional insights into immunotherapeutic agents by discussing their pharmacodynamics, pharmacokinetics, and pertinent interactions. By fostering a comprehensive understanding of immunotherapeutic principles, this program empowers healthcare teams to deliver personalized, efficacious care to patients navigating immunological challenges, thereby advancing the frontier of modern medicine.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify different categories of immunotherapy.</p></list-item><list-item><p>Determine&#x000a0;indicated conditions for each type of immunotherapy.</p></list-item><list-item><p>Identify&#x000a0;some of the contraindications of various forms of immunotherapy.</p></list-item><list-item><p>Select&#x000a0;interprofessional team strategies for improving care coordination and communication to advance immunotherapy, improve outcomes, and minimize adverse events.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23408&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23408">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23408.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Immunotherapy is the use of drugs (eg, immunosuppressors), biologicals (eg, cytokines, monoclonal antibodies, and antisera), vitamins and minerals (eg, zinc, vitamin C, and vitamin B6), transplantation (eg, bone marrow), and immunizations (eg, prophylactic and therapeutic vaccines) to control immune responses. For example, immunotherapy works to upregulate or downregulate the immune system to achieve a therapeutic effect in immunologically mediated disorders, including immunodeficiencies, hypersensitivity reactions, autoimmune diseases, tissue and organ transplantations, malignancies, inflammatory disorders, infectious diseases, and any other disease, where immunotherapy can improve the quality and life expectancy.<xref ref-type="bibr" rid="article-23408.r1">[1]</xref><xref ref-type="bibr" rid="article-23408.r2">[2]</xref><xref ref-type="bibr" rid="article-23408.r3">[3]</xref><xref ref-type="bibr" rid="article-23408.r4">[4]</xref><xref ref-type="bibr" rid="article-23408.r5">[5]</xref><xref ref-type="bibr" rid="article-23408.r6">[6]</xref></p>
        <p>Clinicians describe the use of immunotherapy in some essential disorders of the immune system. The use of immunoglobulins, transfer factor, immunosuppressors, monoclonal antibodies, cytokines, nutritional supplements, and transplantation is listed below.</p>
        <p>
<bold>Immunoglobulin Therapy&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>X-linked agammaglobulinemia</p>
          </list-item>
          <list-item>
            <p>Transient hypogammaglobulinemia of infancy</p>
          </list-item>
          <list-item>
            <p>Variable common immunodeficiency</p>
          </list-item>
          <list-item>
            <p>Selective immunoglobulin deficiencies (except for IgA)</p>
          </list-item>
          <list-item>
            <p>Hyper-IgM syndrome</p>
          </list-item>
          <list-item>
            <p>Lupus-like syndromes</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Use of Transfer Factor (Dialysable Leukocyte Extract)</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Interstitial pneumonia in acquired immunodeficient states</p>
          </list-item>
          <list-item>
            <p>Recurrent viral infections in&#x000a0;immunodeficiency syndromes</p>
          </list-item>
          <list-item>
            <p>Chronic mucocutaneous candidiasis</p>
          </list-item>
          <list-item>
            <p>Primary tuberculosis with immunodeficiency</p>
          </list-item>
          <list-item>
            <p>Wiskott-Aldrich syndrome</p>
          </list-item>
          <list-item>
            <p>Severe combined immunodeficiency disease (SCID)</p>
          </list-item>
          <list-item>
            <p>Chronic active hepatitis</p>
          </list-item>
          <list-item>
            <p>Coccidioidomycosis</p>
          </list-item>
          <list-item>
            <p>Beh&#x000e7;et disease</p>
          </list-item>
          <list-item>
            <p>Aphthous stomatitis</p>
          </list-item>
          <list-item>
            <p>Familial keratoacanthoma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Malignancy &#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Use of Immunosuppressors&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Systemic lupus erythematosus (SLE) &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Wiskott-Aldrich syndrome &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Autoimmune lymphoproliferative syndrome</p>
          </list-item>
          <list-item>
            <p>Idiopathic CD4+ lymphocytopenia</p>
          </list-item>
          <list-item>
            <p>Complement system deficiencies</p>
          </list-item>
          <list-item>
            <p>Various malignancies</p>
          </list-item>
        </list>
        <p>
<bold>Transplantation</bold>
</p>
        <p>
<italic toggle="yes">Bone marrow transplant &#x000a0;</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>RAG-1/RAG-2 SCID</p>
          </list-item>
          <list-item>
            <p>ADA-SCID&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Artemis SCID</p>
          </list-item>
          <list-item>
            <p>Wiskott-Aldrich syndrome</p>
          </list-item>
          <list-item>
            <p>X-linked agammaglobulinemia</p>
          </list-item>
          <list-item>
            <p>Acute leukemia</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Thymus transplant &#x000a0; &#x000a0;</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>DiGeorge syndrome</p>
          </list-item>
        </list>
        <p>
<bold>Immunizations &#x000a0;&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diphtheria, tetanus, and pertussis (DTP)</p>
          </list-item>
          <list-item>
            <p>Inactivated Polio vaccine</p>
          </list-item>
          <list-item>
            <p>Measles, Mumps, and Rubella</p>
          </list-item>
          <list-item>
            <p>Pneumococcal conjugate</p>
          </list-item>
          <list-item>
            <p>Hemophilus B conjugate</p>
          </list-item>
          <list-item>
            <p>Hepatitis B</p>
          </list-item>
          <list-item>
            <p>Varicella</p>
          </list-item>
          <list-item>
            <p>Bacille Calmette-Gu&#x000e9;rin (BCG)</p>
          </list-item>
          <list-item>
            <p>Human Papillomavirus (HPV)</p>
          </list-item>
          <list-item>
            <p>Meningococcal vaccine</p>
          </list-item>
          <list-item>
            <p>Cholera vaccine</p>
          </list-item>
          <list-item>
            <p>Rotavirus vaccine</p>
          </list-item>
          <list-item>
            <p>Yellow fever vaccine</p>
          </list-item>
          <list-item>
            <p>Dengue vaccine&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Use of Cytokines in the Immunotherapy of Advanced Malignancies &#x000a0;&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Interleukin-2</p>
          </list-item>
          <list-item>
            <p>Interleukin-7</p>
          </list-item>
          <list-item>
            <p>Interleukin-12</p>
          </list-item>
          <list-item>
            <p>Interleukin-18</p>
          </list-item>
          <list-item>
            <p>Interleukin-21</p>
          </list-item>
        </list>
        <p>
<bold>Use of Nutritional Supplements (Vitamins A, C, E, and B6, Iron, Zinc, Selenium, and Copper) &#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary immunodeficiency with malnutrition</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Malignancies in general&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Graft-versus-host reaction</p>
          </list-item>
          <list-item>
            <p>Diseases with impaired cell-mediated immunity&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Recurrent and chronic bacterial infections</p>
          </list-item>
          <list-item>
            <p>SCID</p>
          </list-item>
          <list-item>
            <p>HIV/AIDS</p>
          </list-item>
          <list-item>
            <p>Burns &#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Phase III Clinical Trials of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib &#x000a0;&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Relapsed or refractory chronic lymphocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Small lymphocytic lymphoma</p>
          </list-item>
          <list-item>
            <p>Relapsed or refractory Mantle cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma</p>
          </list-item>
        </list>
        <p>
<bold>Use of Interferon Gamma &#x000a0; &#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic granulomatous disease</p>
          </list-item>
          <list-item>
            <p>Bladder carcinoma</p>
          </list-item>
          <list-item>
            <p>Melanoma</p>
          </list-item>
          <list-item>
            <p>Chagas disease</p>
          </list-item>
          <list-item>
            <p>Lepromatous leprosy</p>
          </list-item>
          <list-item>
            <p>HIV/AIDS&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cryptococcal meningitis</p>
          </list-item>
        </list>
        <p>
<bold>Immune Checkpoint Inhibitors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ipilimumab&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nivolumab&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pembrolizumab&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Atezolizumab&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Avelumab &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Durvalumab</p>
          </list-item>
        </list>
        <p>
<bold>Cytokine Antagonists (IL-1RA)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Septic shock</p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease</p>
          </list-item>
          <list-item>
            <p>Ischemia-reperfusion injury</p>
          </list-item>
          <list-item>
            <p>Adult respiratory distress syndrome</p>
          </list-item>
          <list-item>
            <p>Osteoporosis</p>
          </list-item>
          <list-item>
            <p>Polyarteritis nodosa</p>
          </list-item>
          <list-item>
            <p>Glomerulonephritis</p>
          </list-item>
        </list>
        <p>
<bold>Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Accelerate marrow recovery after autologous bone marrow transplantation</p>
          </list-item>
          <list-item>
            <p>Primary neutropenia</p>
          </list-item>
          <list-item>
            <p>Myelodysplasia</p>
          </list-item>
          <list-item>
            <p>Myeloproliferative disorders</p>
          </list-item>
          <list-item>
            <p>AIDS</p>
          </list-item>
          <list-item>
            <p>Aplastic anemia</p>
          </list-item>
          <list-item>
            <p>Neutropenia associated with Felty syndrome&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>CAR T-cell therapy</bold>
</p>
        <p>CAR T-cell therapy has primarily been investigated and approved for certain hematological malignancies, particularly B-cell malignancies. These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>B-cell Acute Lymphoblastic Leukemia (B-ALL): CAR T-cell therapy has&#x000a0;demonstrated remarkable efficacy in treating relapsed or refractory B-ALL, particularly in pediatric and young adult patients.</p>
          </list-item>
          <list-item>
            <p>Diffuse Large B-cell Lymphoma (DLBCL): CAR T-cell therapy has been approved for certain subtypes of DLBCL, including relapsed or refractory DLBCL after&#x000a0;2 or more lines of systemic therapy.</p>
          </list-item>
          <list-item>
            <p>Follicular Lymphoma (FL): CAR T-cell therapy has demonstrated promising results in treating relapsed or refractory FL, especially in patients who have failed multiple lines of therapy.</p>
          </list-item>
          <list-item>
            <p>Mantle Cell Lymphoma (MCL): CAR T-cell therapy has shown efficacy in treating relapsed or refractory MCL, particularly in patients who have failed prior therapies.</p>
          </list-item>
          <list-item>
            <p>Chronic Lymphocytic Leukemia (CLL): While still investigational, CAR T-cell therapy is being studied in CLL, particularly in patients with high-risk disease or those who have relapsed after multiple lines of therapy.</p>
          </list-item>
        </list>
        <p>In addition to these hematological malignancies, CAR T-cell therapy is also being investigated for certain types of solid tumors, although progress in this area has been more limited. Solid tumors being targeted with CAR T-cell therapy include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiple Myeloma: CAR T-cell therapy targeting BCMA (B-cell maturation antigen) has shown promise in treating relapsed or refractory multiple myeloma.</p>
          </list-item>
          <list-item>
            <p>Glioblastoma: CAR T-cell therapy targeting EGFRvIII (epidermal growth factor receptor variant III) has been investigated in glioblastoma, although results have been mixed.</p>
          </list-item>
          <list-item>
            <p>Sarcomas: CAR T-cell therapy is being explored in certain types of sarcomas, including osteosarcoma and synovial sarcoma, although research is still in the early stages.</p>
          </list-item>
        </list>
        <p>While CAR T-cell therapy has shown significant promise in treating certain types of cancer, particularly B-cell malignancies, ongoing research is needed to expand its applicability to other cancer types and improve its efficacy and safety profile.</p>
      </sec>
      <sec id="article-23408.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Intravenous Immunoglobulins (IVIG)</bold>
</p>
        <p>IVIG is a product&#x000a0;isolated&#x000a0;from fractionation pools of thousands of plasma donations collected in blood transfusion services. Traces of IgM, IgA, and cytokines are present in IVIG. IVIGs&#x000a0;have several proposed mechanisms of action including:<xref ref-type="bibr" rid="article-23408.r7">[7]</xref><xref ref-type="bibr" rid="article-23408.r8">[8]</xref><xref ref-type="bibr" rid="article-23408.r9">[9]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Effects of IVIG on activated B-lymphocytes &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Infusion of IVIG results in auto-IgG suppression &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Interaction of Fc fragment with Fc receptors &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Interaction of infused IgG with complement proteins &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Modulation of synthesis of cytokines &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Modulation of cell proliferation and apoptosis &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Remyelination</p>
          </list-item>
          <list-item>
            <p>Neutralizes pathogenic autoantibodies &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Interferes with antigen presentation &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Functional blockade of Fc receptors on splenic macrophages &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Selection of immune repertoires &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Neutralization of bacterial toxins and superantigens &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hindrance of natural killer cell activity &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Inhibition of matrix metalloproteinase-9 &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Suppression of NF-kB activation and IkB degradation &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>G1 cell cycle arrest &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prevention of tumor growth &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Enhances the expansion of Tregs&#x000a0;</p>
          </list-item>
        </list>
        <p>IVIG has been used with some success to improve the symptoms and clinical signs of conditions that include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune thrombocytopenic purpura (ITP)</p>
          </list-item>
          <list-item>
            <p>Guillain-Barre syndrome</p>
          </list-item>
          <list-item>
            <p>Chronic inflammatory demyelinating polyneuropathy</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus (SLE)</p>
          </list-item>
          <list-item>
            <p>Idiopathic inflammatory myopathies</p>
          </list-item>
          <list-item>
            <p>ANCA-associated vasculitis</p>
          </list-item>
          <list-item>
            <p>Multiple motor neuropathy</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis</p>
          </list-item>
          <list-item>
            <p>Kawasaki disease</p>
          </list-item>
          <list-item>
            <p>Autoimmune uveitis</p>
          </list-item>
          <list-item>
            <p>Dermatomyositis</p>
          </list-item>
          <list-item>
            <p>Systemic sclerosis</p>
          </list-item>
          <list-item>
            <p>Sj&#x000f6;gren syndrome</p>
          </list-item>
          <list-item>
            <p>Antiphospholipid antibody syndrome</p>
          </list-item>
          <list-item>
            <p>Still disease</p>
          </list-item>
          <list-item>
            <p>Acute disseminated encephalomyelitis</p>
          </list-item>
          <list-item>
            <p>Diabetic neuropathy</p>
          </list-item>
          <list-item>
            <p>Lambert-Eaton myasthenic syndrome</p>
          </list-item>
          <list-item>
            <p>Opsoclonus-myoclonus</p>
          </list-item>
          <list-item>
            <p>Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections</p>
          </list-item>
          <list-item>
            <p>Polymyositis</p>
          </list-item>
          <list-item>
            <p>Rasmussen encephalitis</p>
          </list-item>
          <list-item>
            <p>Stiff person syndrome</p>
          </list-item>
          <list-item>
            <p>Primary immunodeficiency disorders</p>
          </list-item>
          <list-item>
            <p>Secondary immunodeficiency disorder</p>
          </list-item>
          <list-item>
            <p>Chronic lymphocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Bone marrow transplantation</p>
          </list-item>
          <list-item>
            <p>Treatment-induced neutropenia and thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>AIDS</p>
          </list-item>
          <list-item>
            <p>Autoimmune thyroiditis</p>
          </list-item>
          <list-item>
            <p>Inclusion-body myositis</p>
          </list-item>
          <list-item>
            <p>Graft-versus-host disease</p>
          </list-item>
          <list-item>
            <p>Recurrent pregnancy loss</p>
          </list-item>
          <list-item>
            <p>Cancer</p>
          </list-item>
          <list-item>
            <p>Severe infections</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis</p>
          </list-item>
          <list-item>
            <p>Stevens-Johnson syndrome</p>
          </list-item>
          <list-item>
            <p>Neonatal hemochromatosis</p>
          </list-item>
        </list>
        <p>
<bold>Transfer Factor</bold>
</p>
        <p>Transfer factor is a dialysable extract of leukocytes&#x000a0;that can transfer cell-mediated immunity from one individual to another. It may be used for several pathologies, including immunodeficiencies, viral infections, malignancies, and recurrent fungal infections. Some patients with type I hypersensitivity disorders have&#x000a0;demonstrated a response to this product.<xref ref-type="bibr" rid="article-23408.r10">[10]</xref><xref ref-type="bibr" rid="article-23408.r11">[11]</xref><xref ref-type="bibr" rid="article-23408.r12">[12]</xref></p>
        <p>
<bold>Immunosuppressors</bold>
</p>
        <p>Steroids inhibit cytokine synthesis, affect cell migration, and inhibit the production of leukocytes. Together with chlorambucil, cyclophosphamide acts by covalent alkylation to exert an immunomodulatory effect. This combination inhibits the separation of DNA strands during replication. Methotrexate is an analog of folic acid and blocks pathways essential for DNA synthesis. Azathioprine is a drug that can convert to 6-mercaptopurine to be incorporated into DNA as a fraudulent base.<xref ref-type="bibr" rid="article-23408.r13">[13]</xref></p>
        <p>
<bold>Transplantation</bold>
</p>
        <p>Transplantation is a promising solution for many rare diseases that can manifest as primary immunodeficiencies, including severe-combined immunodeficiency disorder (SCID), DiGeorge syndrome, Wiskott-Aldrich syndrome, and X-linked agammaglobulinemia.<xref ref-type="bibr" rid="article-23408.r14">[14]</xref></p>
        <p>
<bold>Several Immunotherapy Modalities Used in Cancer Treatment</bold>
</p>
        <p>The use of monoclonal antibodies can be used in cancer immunotherapy (eg, immune checkpoint inhibitors (ICIs). These drugs include pembrolizumab and atezolizumab. These ICIs unlock the immune system, which is then able to recognize tumors and kill them.<xref ref-type="bibr" rid="article-23408.r4">[4]</xref></p>
        <p>Cytokines&#x000a0;have successfully&#x000a0;treated certain malignancies. For example, IL-2 combined with interferon-&#x003b3; for renal carcinoma, interferon-&#x003b1; and &#x003b2; for hairy leukemia, and TNF-&#x003b1; used in various tumors caused a notable reduction of the mass. These cytokines upregulated the immune system by stimulating T-cell and NK cell activation and increased MHC class I expression.</p>
        <p>CAR T-cell therapy, or Chimeric Antigen Receptor T-cell therapy, is a groundbreaking immunotherapy approach used to treat certain types of cancer. Here are the key principles:<xref ref-type="bibr" rid="article-23408.r15">[15]</xref><xref ref-type="bibr" rid="article-23408.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>CAR Structure: CARs are synthetic receptors that redirect T-cells to recognize and attack cancer cells. They consist of an extracellular antigen-binding domain, a transmembrane domain, and intracellular signaling domains.</p>
          </list-item>
          <list-item>
            <p>Antigen Recognition: The extracellular domain of the CAR is engineered to recognize a specific antigen present on the surface of cancer cells. This antigen is often a tumor-associated antigen (TAA) or a cancer-specific antigen.</p>
          </list-item>
          <list-item>
            <p>T-Cell Activation: Upon binding to the target antigen, the CAR activates the T-cell, leading to its proliferation, cytokine release, and cytotoxic activity against the cancer cell.</p>
          </list-item>
          <list-item>
            <p>Persistence and Memory: CAR T-cells are designed to persist in the body and form memory cells, providing long-term surveillance against cancer recurrence.</p>
          </list-item>
          <list-item>
            <p>Treatment Process: The CAR T-cell therapy process involves collecting a patient's T-cells through leukapheresis, genetically engineering them to express the CAR, expanding them in the laboratory, and then reinfusing them into the patient.</p>
          </list-item>
          <list-item>
            <p>Clinical Applications: CAR T-cell therapy has shown remarkable success in treating certain hematological malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and certain types of non-Hodgkin lymphoma (NHL). It is also being investigated for solid tumors.</p>
          </list-item>
          <list-item>
            <p>Challenges and Side Effects: Despite its efficacy, CAR T-cell therapy can be associated with side effects such as cytokine release syndrome (CRS) and neurotoxicity. Managing these side effects and improving the therapy's safety profile are ongoing research areas.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23408.s4" sec-type="Administration">
        <title>Administration</title>
        <p>IVIG can be administered intravenously&#x000a0;with a dosage of 0.4 g/kg for&#x000a0;5 days to treat Guillain&#x02013;Barr&#x000e9; syndrome, but the dose varies depending on the pathology. Low-dose cyclophosphamide has had a more significant impact on cell-mediated immunity. In humans, a low-dose bolus of 600 mg/m B-cells decreases more than T-cells, and among T-cells, the CD8 subset diminishes more than CD4 cells.</p>
      </sec>
      <sec id="article-23408.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of immunotherapy include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cyclophosphamide and chlorambucil include bone marrow toxicity; therefore, leukopenia requires monitoring.</p>
          </list-item>
          <list-item>
            <p>Azathioprine produces reductions of both T and B-lymphocytes.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Giving transfer factor requires caution in patients with Type I hypersensitivity reactions to prevent anaphylaxis.</p>
          </list-item>
          <list-item>
            <p>Interleukins must be given in a low dose to prevent side effects and decrease morbidity.</p>
          </list-item>
          <list-item>
            <p>Glucocorticoid therapy causes negative calcium balance, leading to osteoporosis, increased appetite,&#x000a0;central&#x000a0;obesity, impaired wound healing, increased risk of infection, suppression of the hypothalamic-pituitary-adrenal axis, and growth arrest in children. Other side effects&#x000a0;include myopathy, avascular necrosis, hypertension, plethora, hyperlipidemia, and edema.</p>
          </list-item>
          <list-item>
            <p>Adverse&#x000a0;effects of NSAID therapy include gastritis, duodenal and gastric ulcers, decreased creatinine clearance, acute renal failure, interstitial nephritis, confusion, memory loss, and personality changes, especially in older patients.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23408.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients with T-cell deficiencies (including SCID) should not be vaccinated with the live-attenuated vaccine because there is a danger that the antigen will reverse its pathogenicity and cause illness. Patients with IgA deficiency should not receive IgG preparations that are not highly purified because there is a danger of a hypersensitivity reaction. If the immune system does not recognize the IgA in the preparation, this can be life-threatening. Patients with DiGeorge syndrome should not be transplanted with a thymus older than 14 weeks because a graft-versus-host reaction may occur.&#x000a0;The donor can be&#x000a0;a sibling or a parent if genetic compatibility exists. Blood group compatibility for major antigens (such as the ABO system and Rh system) must match.<xref ref-type="bibr" rid="article-23408.r14">[14]</xref><xref ref-type="bibr" rid="article-23408.r16">[16]</xref></p>
      </sec>
      <sec id="article-23408.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The use of IVIG has expanded significantly over the past&#x000a0;3 decades.&#x000a0;Providing care to patients with immune deficiencies is most effective with an interprofessional team that includes clinicians (MDs, DOs, NPs, PAs), specialists, hematology nurses, and pharmacists. While IVIG is effective, patients need to understand that the therapy is not benign and is associated with adverse effects. Close monitoring of patients is necessary because of allergies, anaphylaxis, and graft-versus-host reactions. Given the potential for adverse events with immunotherapy, the entire team must be vigilant for these reactions. The pharmacist must have close involvement with nursing and the clinician staff, with all members of the interprofessional team informed and communicating regarding the adverse event profile. This is so immunotherapy has the best chance to help the patient with minimal chance for&#x000a0;adverse effects.</p>
      </sec>
      <sec id="article-23408.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23408&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23408">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23408/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23408">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23408.s9">
        <title>References</title>
        <ref id="article-23408.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roli&#x00144;ski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grywalska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pyzik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dzik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Opoka-Winiarska</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Surdacka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burdan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piro&#x0017c;y&#x00144;ski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grabarczyk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Staros&#x00142;awska</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Interferon alpha as antiviral therapy in chronic active Epstein-Barr virus disease with interstitial pneumonia - case report.</article-title>
            <source>BMC Infect Dis</source>
            <year>2018</year>
            <month>Apr</month>
            <day>20</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>190</fpage>
            <pub-id pub-id-type="pmid">29678144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhoeven</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stoppelenburg</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Meyer-Wentrup</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boes</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy.</article-title>
            <source>Clin Immunol</source>
            <year>2018</year>
            <month>May</month>
            <volume>190</volume>
            <fpage>22</fpage>
            <page-range>22-31</page-range>
            <pub-id pub-id-type="pmid">29499421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model.</article-title>
            <source>Exp Ther Med</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>5394</fpage>
            <page-range>5394-5402</page-range>
            <pub-id pub-id-type="pmid">29844804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thangamathesvaran</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint inhibitors and radiotherapy-concept and review of current literature.</article-title>
            <source>Ann Transl Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>8</issue>
            <fpage>155</fpage>
            <pub-id pub-id-type="pmid">29862244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karkhah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Javanian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ebrahimpour</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The role of regulatory T cells in immunopathogenesis and immunotherapy of viral infections.</article-title>
            <source>Infect Genet Evol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>59</volume>
            <fpage>32</fpage>
            <page-range>32-37</page-range>
            <pub-id pub-id-type="pmid">29413883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maude</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Aplenc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bunin</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Mahnke</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Melenhorst</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rheingold</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teachey</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>June</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Chimeric antigen receptor T cells for sustained remissions in leukemia.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Oct</month>
            <day>16</day>
            <volume>371</volume>
            <issue>16</issue>
            <fpage>1507</fpage>
            <page-range>1507-17</page-range>
            <pub-id pub-id-type="pmid">25317870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Querido</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weigert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adrag&#x000e3;o</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Henriques</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Birne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Matias</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jorge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Intravenous Immunoglobulin and Rituximab in HLA Highly Sensitized Kidney Transplant Recipients.</article-title>
            <source>Transplant Proc</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>723</fpage>
            <page-range>723-727</page-range>
            <pub-id pub-id-type="pmid">29661424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Garcia-Robledo</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Plata</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Urbano</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Posso-Osorio</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rios-Serna</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Barrera</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Tob&#x000f3;n</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus.</article-title>
            <source>Autoimmun Rev</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>279</fpage>
            <page-range>279-286</page-range>
            <pub-id pub-id-type="pmid">30639648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Navarro-Puerto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Damodar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramanan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>C'</given-names>
              </name>
              <name>
                <surname>Rucker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pinciaro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barrera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aragon&#x000e9;s</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ayguasanosa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of intravenous immunoglobulin (Flebogamma<sup>&#x000ae;</sup> 10% DIF) in patients with immune thrombocytopenic purpura.</article-title>
            <source>Immunotherapy</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-89</page-range>
            <pub-id pub-id-type="pmid">30499734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Preparation and immunological evaluation of oral solution of egg yolk-derived hepatitis B virus-specific transfer factor].</article-title>
            <source>Nan Fang Yi Ke Da Xue Xue Bao</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>1827</fpage>
            <page-range>1827-30</page-range>
            <pub-id pub-id-type="pmid">24369255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pizza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Viza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Vinci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Palareti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cuzzocrea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fornarola</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Baricordi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses.</article-title>
            <source>Biotherapy</source>
            <year>1996</year>
            <volume>9</volume>
            <issue>1-3</issue>
            <fpage>67</fpage>
            <page-range>67-72</page-range>
            <pub-id pub-id-type="pmid">8993760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikula</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pistl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosocha</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Dialyzable leukocyte extract used in the prevention of Salmonella infection in calves.</article-title>
            <source>Vet Immunol Immunopathol</source>
            <year>1992</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>1-2</issue>
            <fpage>113</fpage>
            <page-range>113-24</page-range>
            <pub-id pub-id-type="pmid">1604794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cantarovich</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vistoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Soulillou</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Immunosuppression minimization in kidney transplantation.</article-title>
            <source>Front Biosci</source>
            <year>2008</year>
            <month>Jan</month>
            <day>01</day>
            <volume>13</volume>
            <fpage>1413</fpage>
            <page-range>1413-32</page-range>
            <pub-id pub-id-type="pmid">17981639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Qurie</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Immunodeficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29763203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dunmall</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.</article-title>
            <source>Cancer Lett</source>
            <year>2024</year>
            <month>Apr</month>
            <day>10</day>
            <volume>591</volume>
            <fpage>216871</fpage>
            <pub-id pub-id-type="pmid">38604310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23408.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Macartney</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beresford</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sheppeard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection.</article-title>
            <source>Vaccine</source>
            <year>2018</year>
            <month>Jun</month>
            <day>22</day>
            <volume>36</volume>
            <issue>27</issue>
            <fpage>3890</fpage>
            <page-range>3890-3893</page-range>
            <pub-id pub-id-type="pmid">29807711</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
